Minimal Residual Disease by Flow Cytometry: Latest Insights on Validation

Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome in patients with hematological conditions.1 There is now much interest around early use of MRD as a surrogate marker of survival, especially given its potential to accelerate trial reporting and be accepted as a primary/secondary trial endpoint. Here, we explore how next-generation flow cytometry ('flow') is integral to evaluating MRD.

Copy and paste this URL:

https://biopharma.labcorp.com/latest-thinking/explore-library/detail.html/covance/assetLibrary/Blog/Greenfield3801.jpg